Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has announced a definitive agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease (COPD). TRB-1 and TRB-2, the first products developed by Transpire Bio, will be indicated for the treatment of asthma and COPD, intended for advanced markets.
“Our mission is to improve access to important, life-saving inhaled therapies, and to introduce new inhaled therapies to help address areas of significant unmet medical need,” says Dr. Xian-Ming Zeng, CEO of Transpire Bio. “TRB-1 and TRB-2 are our first offerings in development which will help improve access for potentially millions of patients. We are very excited to be working with Recipharm to advance these important medicines.”
Jean-Francois Hilaire, Recipharm executive committee member, head of business unit advanced delivery systems, adds, “Recipharm is very pleased to be leveraging its broad experience and expertise in developing and commercializing inhalation technologies and products in support of the development and advancement of Transpire Bio’s TRB-1 and TRB-2 respiratory products. We look forward to the collaboration.”
According to statistics from the World Health Organization, asthma affected approximately 262 million people in 2019, and accounted for approximately 455,000 deaths. COPD was the third-leading cause of death in 2019, with approximately 3.2 million lives lost.
Transpire Bio Inc. is a U.S.-based, development-stage biopharmaceutical company headquartered in Miami, Fla. Recipharm is a leading contract development and manufacturing organization in the pharmaceutical industry, with almost 9,000 employees.
